Sandoz Expects ‘Trough Year’ In 2023 As It Counts Cost Of Spinoff

Novartis Management Outlines Path Ahead For Sandoz As It Prepares To Separate

 
• By David Wallace
  
Finger drawing curve upwards
Sandoz expects a trough for operating income in 2023, followed by growth • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business